Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Inclusion Criteria: * Patient with a TP53wt locally advanced or metastatic solid malignancy and with measurable or non-measurable (but evaluable) disease as determined by RECIST 1.1 criteria. * Patients with the TP53wt hematological tumors (AML, ALL, HR-MDS) who have failed prior therapies or who are considered inappropriate candidates for standard induction therapy. Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Prior treatment with compounds with the same mode of action * Subjects with significant or uncontrolled cardiovascular disease * History of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism * Previous and concomitant therapy that precludes enrollment, as defined in the protocol * Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or Hepatitis C infection * Patients who have undergone major surgery within the 2 weeks prior to starting study treatment or who have not fully recovered from previous surgery * Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 2 weeks after study drug discontinuation * Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply